Fairview Capital III

Inbox Health Corp. specializes in developing a patient communication platform tailored for medical billers in the United States. Founded in 2014 and based in New Haven, Connecticut, the company offers a platform that automates the patient communication process through bi-directional correspondence, proprietary algorithms, machine learning, and artificial intelligence. This technology helps patients better understand their medical bills and provides access to various payment options. By analyzing data across its customer base, Inbox Health enables billers to customize each patient's billing and communication experience, ultimately enhancing patient collections and overall satisfaction. The company's mission is to significantly reduce administrative inefficiencies in healthcare by streamlining the billing and payment processes for patients.

Covr Financial Technologies, Inc. is a digitally enabled brokerage general agency that specializes in providing life, long-term care, and disability insurance solutions for financial institutions and their clients. Founded in 2016 and based in Boise, Idaho, Covr offers a range of digital platforms, including Covr Advisor for financial advisors, Covr Consumer for banks and credit unions to sell insurance online, and Covr Insights for managing in-force life insurance policies. The company serves over 24,000 financial advisors and approximately 13 million customers across 30 financial institutions, such as wealth management firms and credit unions. Covr's technology empowers financial professionals to address their clients' insurance needs effectively while facilitating direct access to products for consumers. The company has garnered the support of prominent venture capital firms and boasts an advisory board composed of notable leaders from the financial services sector.

Inbox Health Corp. specializes in developing a patient communication platform tailored for medical billers in the United States. Founded in 2014 and based in New Haven, Connecticut, the company offers a platform that automates the patient communication process through bi-directional correspondence, proprietary algorithms, machine learning, and artificial intelligence. This technology helps patients better understand their medical bills and provides access to various payment options. By analyzing data across its customer base, Inbox Health enables billers to customize each patient's billing and communication experience, ultimately enhancing patient collections and overall satisfaction. The company's mission is to significantly reduce administrative inefficiencies in healthcare by streamlining the billing and payment processes for patients.

Covr Financial Technologies, Inc. is a digitally enabled brokerage general agency that specializes in providing life, long-term care, and disability insurance solutions for financial institutions and their clients. Founded in 2016 and based in Boise, Idaho, Covr offers a range of digital platforms, including Covr Advisor for financial advisors, Covr Consumer for banks and credit unions to sell insurance online, and Covr Insights for managing in-force life insurance policies. The company serves over 24,000 financial advisors and approximately 13 million customers across 30 financial institutions, such as wealth management firms and credit unions. Covr's technology empowers financial professionals to address their clients' insurance needs effectively while facilitating direct access to products for consumers. The company has garnered the support of prominent venture capital firms and boasts an advisory board composed of notable leaders from the financial services sector.

Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.